Kadmon (KDMN) Stock Rating Reaffirmed by HC Wainwright
Kadmon (NYSE:KDMN)‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a report issued on Friday. They presently have a $25.00 target price on the stock.
A number of other brokerages also recently issued reports on KDMN. WBB Securities downgraded shares of Kadmon from a “hold” rating to a “sell” rating and set a $3.00 price objective for the company. in a research report on Monday, October 9th. Zacks Investment Research raised shares of Kadmon from a “sell” rating to a “hold” rating in a research report on Tuesday, November 21st. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $9.75.
Kadmon (NYSE:KDMN) traded down $0.06 during trading hours on Friday, reaching $3.58. 241,800 shares of the company’s stock were exchanged, compared to its average volume of 289,422. Kadmon has a fifty-two week low of $2.05 and a fifty-two week high of $5.93.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Goldman Sachs Group Inc. purchased a new stake in Kadmon in the 2nd quarter worth $114,000. Bank of New York Mellon Corp purchased a new stake in Kadmon in the 3rd quarter worth $119,000. Renaissance Technologies LLC purchased a new stake in Kadmon in the 1st quarter worth $158,000. Old West Investment Management LLC purchased a new stake in Kadmon in the 3rd quarter worth $169,000. Finally, Wells Fargo & Company MN lifted its stake in Kadmon by 17.0% in the 2nd quarter. Wells Fargo & Company MN now owns 60,033 shares of the company’s stock worth $234,000 after purchasing an additional 8,742 shares in the last quarter. Institutional investors own 51.90% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Kadmon (KDMN) Stock Rating Reaffirmed by HC Wainwright” was published by American Banking News and is owned by of American Banking News. If you are viewing this story on another website, it was illegally copied and republished in violation of US & international copyright and trademark laws. The original version of this story can be read at https://www.americanbankingnews.com/2017/12/15/kadmon-kdmn-stock-rating-reaffirmed-by-hc-wainwright.html.
Kadmon Holdings, Inc is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases.
Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.